查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1741184

基因组癌症检测市场：按检测类型、癌症类型、技术、最终用户、生物标记类型、服务供应商、应用、检测环境和地区划分

Genomic Cancer Testing Market, By Test Type, By Cancer Type, By Technology, By End-User, By Biomarker Type, By Service Provider, By Application, By Testing Setting, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3个工作天内

价格
简介目录

基因组癌症检测市场规模预计在 2025 年达到 220 亿美元，预计到 2032 年将达到 648.5 亿美元，2025 年至 2032 年的复合年增长率为 16.7%。

报告范围 报告详细信息
基准年 2024 2025年的市场规模 220亿美元
效能数据 2020-2024 预测期 2025-2032
预测期：2025-2032年复合年增长率： 16.70% 2032年价值预测 648.5亿美元

基因组癌症检测正在迅速改变肿瘤学领域。透过分析癌细胞的基因组成，这些检测可以深入了解导致患者患病的突变。这种个人化方法使临床医生能够根据个体的基因谱制定个人化治疗方案，并选择直接针对异常基因的治疗药物。肿瘤基因组分析有助于预测患者对某些药物的反应，检测提示高復发风险的基因标记，并识别可以阻断以阻止癌症生长的生物路径。随着基因组技术的不断进步，癌症检测正变得越来越全面且经济实惠。预计未来几年，这将显着改善许多癌症患者的预后。

市场动态：

全球基因组癌症检测市场主要受全球癌症发生率上升和随之而来的精准医疗需求的驱动。次世代定序(NGS) 技术在生物标记识别的日益广泛应用也推动了市场成长。然而，缺乏基因组分析所需的基础设施和熟练的专业人员构成了重大挑战，尤其是在开发中国家。检测程序的高成本也进一步限制了它的广泛应用。然而，私人和公共机构为开发新型诊断工具而提供的资金提供了有利可图的机会。诊断公司和癌症中心之间的伙伴关係旨在扩大基因组分析的管道。检测可操作的基因组变异和检验伴随诊断的其他策略措施将进一步刺激基因组癌症检测市场。此外，预计市场参与企业之间加强合作将在预测期内推动市场成长。例如，2023年4月，人工智慧和精准医疗领域的领导者Tempus宣布与礼来公司（Eli Lilly and Company）达成一项新的合作，旨在扩大合格的进行性或转移性甲状腺髓样癌（MTC）以及进行性或转移性非髓样甲状腺癌（non-MTC）患者的基因组检测覆盖范围。此次合作将免费提供Tempus的分子分析服务，同时与医师合作，透过更广泛的基因组检测，为病患提供数据驱动的医疗服务。

本研究的主要特点

  • 本报告对全球基因组癌症检测市场进行了详细分析，并提供了 2025 年至 2032 年期间的市场规模和预测年复合成长率（CAGR%），以 2024 年为基准年。
  • 它还强调了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。
  • 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
  • 全球基因组癌症检测市场的主要企业是根据公司亮点、产品系列、关键亮点、财务绩效和策略等参数进行的分析。
  • 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴车型、市场扩张和行销策略做出明智的决策。
  • 全球基因组癌症检测市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
  • 可以透过用于分析全球基因组癌症检测市场的各种策略矩阵来促进相关人员的决策。

目录

第一章 调查目的与前提条件

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告描述
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规与趋势分析

  • 市场动态
    • 癌症发生率增加
    • 高成本
    • 癌症发生率增加
  • 影响分析
  • 主要亮点
  • 监管情景
  • 产品发布/核准
  • PEST分析
  • 波特分析
  • 併购场景

4. 全球基因组癌症检测市场-冠状病毒（COVID-19）大流行的影响

  • COVID-19流行病学
  • 供需侧分析
  • 经济影响

5. 全球基因组癌症检测市场（依检测类型），2020 年至 2032 年

  • 基因组分析测试
  • 液态生物检体
  • 伴随诊断测试
  • 药物基因组学检测
  • 遗传性癌症检测
  • 其他专门的基因组测试

6. 全球基因组癌症检测市场（以癌症类型），2020 年至 2032 年

  • 乳癌
  • 肺癌
  • 大肠直肠癌
  • 摄护腺癌
  • 卵巢癌
  • 黑色素瘤
  • 白血病
  • 淋巴瘤
  • 其他特定癌症类型

7. 全球基因组癌症检测市场（依技术划分），2020 年至 2032 年

  • 次世代定序（NGS）
  • 聚合酵素链锁反应（PCR）
  • 萤光原位杂合反应（FISH）
  • 微阵列
  • 免疫组织化学（IHC）
  • 其他基因组检测技术

8. 全球基因组癌症检测市场（依最终用户划分），2020 年至 2032 年

  • 医院
  • 诊断实验室
  • 学术研究所
  • 癌症中心
  • 其他医疗保健提供者

9. 全球基因组癌症检测市场（依生物标记类型），2020 年至 2032 年

  • 基因生物标记
  • 蛋白质生物标记
  • 分子生物标记
  • 表观遗传生物标记

10. 全球基因组癌症检测市场（按服务供应商划分），2020 年至 2032 年

  • 诊断实验室
  • 生技公司
  • 製药公司
  • 合约研究组织（CRO）

第 11 章。 2020 年至 2032 年按地区分類的全球基因组癌症检测市场

  • 北美洲
      • 美国
      • 加拿大
  • 拉丁美洲
      • 巴西
      • 墨西哥
      • 阿根廷
      • 其他拉丁美洲
  • 欧洲
      • 英国
      • 德国
      • 义大利
      • 法国
      • 西班牙
      • 俄罗斯
      • 其他欧洲国家
  • 亚太地区
      • 中国
      • 印度
      • 日本
      • ASEAN
      • 澳洲
      • 韩国
      • 其他亚太地区
  • 中东
      • GCC
      • 以色列
      • 其他中东地区
  • 非洲
      • 北非
      • 中部非洲
      • 南非

第十二章竞争格局

  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • Qiagen NV
  • F.Hoffmann-La Roche Ltd.
  • Foundation Medicine, Inc.（Roche）
  • Invitae Corporation
  • NeoGenomics Laboratories, Inc.
  • Myriad Genetics, Inc.
  • Genomic Health, Inc.（Exact Sciences Corporation）
  • Caris Life Sciences
  • ArcherDX, Inc.（Invitae Corporation）
  • Guardant Health, Inc.
  • Personal Genome Diagnostics Inc.
  • Biocept, Inc.
  • Tempus Labs, Inc.

第十三章 章节

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI5914

Genomic Cancer Testing Market is estimated to be valued at USD 22.00 Bn in 2025 and is expected to reach USD 64.85 Bn by 2032, growing at a compound annual growth rate (CAGR) of 16.7% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 22.00 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 16.70% 2032 Value Projection: USD 64.85 Bn

Genomic cancer testing is rapidly transforming the field of oncology. It involves analyzing the genetic makeup of cancer cells to gain insights into the mutations driving a patient's disease. This personalized approach enables clinicians to tailor treatment based on an individual's genetic profile and select therapeutics that directly target the abnormalities present. The genomic analysis of a tumor helps predict response to certain drugs, checks for genetic markers that may indicate higher risk of recurrence, and pinpoints biological pathways that can be blocked to stop cancer growth. With continued advances in genomic technologies, cancer testing is becoming more comprehensive and affordable. This is expected to significantly improve outcomes for many cancer patients in the coming years.

Market Dynamics:

The global genomic cancer testing market is primarily driven by rising cancer burden worldwide and subsequent demand for precision medicine approaches. Growing application of next-generation sequencing (NGS) technologies for biomarker identification is also fueling market growth. However, lack of infrastructure and skilled professionals required for genomic analysis poses a major challenge, especially in developing nations. High cost of testing procedures further limits widespread adoption. Yet funding from private and public bodies to develop novel diagnostic tools presents lucrative opportunities. Partnerships between diagnostic companies and cancer centers aim to expand access to genomic profiling. Other strategic initiatives to detect actionable genomic alterations and validate companion diagnostics will further stimulate the genomic cancer testing market. MOrevoer, increasing collaboration between market players is expected to drive the market growth over forecast period. For instance, in April 2023, Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration sponsored by Eli Lilly and Company designed to expand access to genomic testing for eligible patients who have advanced or metastatic medullary thyroid cancer (MTC) OR advanced or metastatic non-medullary thyroid cancer (non-MTC). This collaboration offers Tempus' molecular profiling offerings at no cost while simultaneously working with physicians to support them in providing data-driven treatment to their patients with the use of broad-panel genomic testing.

Key features of the study:

  • This report provides in-depth analysis of the global genomic cancer testing market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global genomic cancer testing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Illumina, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., F. Hoffmann-La Roche Ltd., Foundation Medicine, Inc. (Roche), Invitae Corporation, NeoGenomics Laboratories, Inc., Myriad Genetics, Inc., Genomic Health, Inc. (Exact Sciences Corporation), Caris Life Sciences, ArcherDX, Inc. (Invitae Corporation), Guardant Health, Inc., Personal Genome Diagnostics Inc., Biocept, Inc., and Tempus Labs, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global genomic cancer testing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global genomic cancer testing market

Detailed Segmentation:

  • Global Genomic Cancer Testing Market, By Test Type:
    • Genomic Profiling Tests
    • Liquid Biopsy Tests
    • Companion Diagnostic Tests
    • Pharmacogenomic Tests
    • Hereditary Cancer Tests
    • Other specialized genomic tests
  • Global Genomic Cancer Testing Market, By Cancer Type:
    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Ovarian Cancer
    • Melanoma
    • Leukemia
    • Lymphoma
    • Other specific cancer types
  • Global Genomic Cancer Testing Market, By Technology:
    • Next-Generation Sequencing (NGS)
    • Polymerase Chain Reaction (PCR)
    • Fluorescence In Situ Hybridization (FISH)
    • Microarray
    • Immunohistochemistry (IHC)
    • Other genomic testing technologies
  • Global Genomic Cancer Testing Market, By End User:
    • Hospitals
    • Diagnostic Laboratories
    • Academic and Research Institutions
    • Cancer Centers
    • Other healthcare providers
  • Global Genomic Cancer Testing Market, By Biomarker Type:
    • Genetic Biomarkers
    • Protein Biomarkers
    • Molecular Biomarkers
    • Epigenetic Biomarkers
  • Global Genomic Cancer Testing Market, By Service Provider:
    • Diagnostic Laboratories
    • Biotechnology Companies
    • Pharmaceutical Companies
    • Contract Research Organizations (CROs)
  • Global Genomic Cancer Testing Market, By Application:
    • Targeted Therapy Selection
    • Disease Monitoring
    • Prognostic Testing
    • Companion Diagnostics
    • Risk Assessment
    • Pharmacogenomic Testing
  • Global Genomic Cancer Testing Market, By Testing Setting:
    • In-House Testing
    • Outsourced Testing
  • Global Genomic Cancer Testing Market, By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
  • Company Profiles:
    • Illumina, Inc.
    • Thermo Fisher Scientific, Inc.
    • Qiagen N.V.
    • F. Hoffmann-La Roche Ltd.
    • Foundation Medicine, Inc. (Roche)
    • Invitae Corporation
    • NeoGenomics Laboratories, Inc.
    • Myriad Genetics, Inc.
    • Genomic Health, Inc. (Exact Sciences Corporation)
    • Caris Life Sciences
    • ArcherDX, Inc. (Invitae Corporation)
    • Guardant Health, Inc.
    • Personal Genome Diagnostics Inc.
    • Biocept, Inc.
    • Tempus Labs, Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Genomic Cancer Testing, By Test Type
    • Market Genomic Cancer Testing, By Cancer Type
    • Market Genomic Cancer Testing, By Technology
    • Market Genomic Cancer Testing, By End User
    • Market Genomic Cancer Testing, By Biomarker Type
    • Market Genomic Cancer Testing, By Service Provider
    • Market Genomic Cancer Testing, By Application
    • Market Genomic Cancer Testing, By Testing Setting
    • Market Genomic Cancer Testing, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing Cancer Incidence
    • High Costs
    • Increasing Cancer Incidence
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Genomic Cancer Testing Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Genomic Cancer Testing Market, By Test Type, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Genomic Profiling Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Liquid Biopsy Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Companion Diagnostic Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Pharmacogenomic Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Hereditary Cancer Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Other specialized genomic tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Genomic Cancer Testing Market, By Cancer Type, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Colorectal Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Prostate Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Ovarian Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Melanoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Leukemia
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Lymphoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Other specific cancer types
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Genomic Cancer Testing Market, By Technology, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Next-Generation Sequencing (NGS)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Polymerase Chain Reaction (PCR)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Fluorescence In Situ Hybridization (FISH)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Microarray
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Immunohistochemistry (IHC)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Other genomic testing technologies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Global Genomic Cancer Testing Market, By End User, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Diagnostic Laboratories
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Academic and Research Institutions
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Cancer Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Other healthcare providers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

9. Global Genomic Cancer Testing Market, By Biomarker Type, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Genetic Biomarkers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Protein Biomarkers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Molecular Biomarkers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Epigenetic Biomarkers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

10. Global Genomic Cancer Testing Market, By Service Provider, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021- 2032
    • Segment Trends
  • Diagnostic Laboratories
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Biotechnology Companies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Pharmaceutical Companies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Contract Research Organizations (CROs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

11. Global Genomic Cancer Testing Market, By Region, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Region, 2021-2032
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Service Provider, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Testing Setting, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Service Provider, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Testing Setting, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Service Provider, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Testing Setting, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Service Provider, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Testing Setting, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Service Provider, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Testing Setting, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032,(US$ Bn)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Service Provider, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Testing Setting, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region , 2020-2032,(US$ Bn)
      • North Africa
      • Central Africa
      • South Africa

12. Competitive Landscape

  • Illumina, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Thermo Fisher Scientific, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Qiagen N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • F.Hoffmann-La Roche Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Foundation Medicine, Inc. (Roche)
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Invitae Corporation
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • NeoGenomics Laboratories, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Myriad Genetics, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Genomic Health, Inc. (Exact Sciences Corporation)
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Caris Life Sciences
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • ArcherDX, Inc. (Invitae Corporation)
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Guardant Health, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Personal Genome Diagnostics Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Biocept, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Tempus Labs, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Analyst Views
  • Analyst Views

13. Section

  • Research Methodology
  • About us